newsfilter
← Latest News
GlobeNewswire·

Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

  • Maze Therapeutics reported Q2 2026 financial results with $495 million in cash, cash equivalents, & marketable securities, supporting a runway into 2029
  • Enrollment in the Phase 2 HORIZON trial for MZE829 is ongoing, with updated data from three cohorts expected in late 2026 or early 2027
  • The Phase 2 CIPheR trial for MZE782 in PKU has initiated, with topline data anticipated in 2027
  • A Phase 2 trial for MZE782 in CKD is on track to initiate in the first half of 2027
  • Maze plans to launch a pivotal trial for MZE829 in the first half of 2027, subject to regulatory feedback
  • Maze completed a registered offering in April 2026 for approximately $150 million in gross proceeds
  • License revenue of $20 million was recognized in the first half of 2026 following a milestone achievement with Shionogi & Co., Ltd.
  • Research & development expenses were $69.1 million for the six months ended June 30, 2026, reflecting increased clinical development costs
  • General & administrative expenses totaled $25.5 million for the six months ended June 30, 2026
  • The company reported a net loss of $68.9 million, or $1.22 per share, for the six months ended June 30, 2026